Viral vaccines and viral vectors used in biotherapeutic applications carry the risk of microbial contamination, which must be addressed.
Anissa Boumlic
Advertisement
Anissa Boumlic, PHD, is associate director EMEA vaccine and viral therapies, MilliporeSigma.
Articles by Anissa Boumlic
Advertisement
Latest Updated Articles
Ensuring Viral Safety of Viral Vaccines and VectorsPublished: September 1st 2018 | Updated:
Advertisement
Advertisement
Trending on BioPharm International
1
EU Biopharma Strategy: Scaling Up to Tackle Funding Gaps and Drive Innovation
2
Advances in Continuous Manufacturing, Drug Delivery Lead CPHI Pharma Awards 2025
3
Strategic Shifts for Speed, Resilience, and Long-Term Sustainability in Biomanufacturing
4
Regulatory Challenges for Global Manufacturing of Vaccines
5
